News

The company expects to initiate the Phase I clinical study for VGX-3100 in patients in a multi-center study in the third quarter of 2008. VGX-3100 is said to

Echo’s pilot clinical study will enroll 10 patients with diabetes (either Type 1 or Type 2) and will compare data obtained from its Symphony tCGM system with both

VioQuest’s Xyfid is also intended to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis and other dry

Data from two preclinical studies demonstrated that the three molecules showed statistically superior oral efficacy as well as evidence for improved metabolic and pharmacokinetic profiles compared to an

Before joining Bausch & Lomb, Dr Sheets served as global president and CEO of Hoya Surgical Optics. Previously, Dr Sheets was worldwide vice president of R&D, and chief

The agreement with Boston University encompasses therapeutic applications for SIRT1 modulators in metabolic diseases, including obesity and diabetes, as well as therapeutic modulation of SIRT1 for anti-angiogenic activity

Under the terms of the agreement, Danisco will obtain worldwide exclusive rights to commercialize the product or products developed under this collaboration. In return, Direvo will receive R&D

The subscription by Ipsen for 35.25 million new ordinary shares of GBP0.05 each in the capital of Vernalis, as part of the purchase arrangements, has also been completed.

This approval is conditional upon the company providing some additional information to the FDA. Walter Cuevas, CEO of Interventional Spine, said: “We believe that the PercuDyn System is